Connect with us

Headlines

Eye Health Company Raises $27M in IPO

mm

Published

on

It’s developing products for glaucoma and other conditions.

NEW YORK — Biopharmaceutical company Eyenovia Inc. has closed on an initial public offering of 2.73 million shares of common stock.

Eyenovia received $27.3 million in gross proceeds from the offering, according to a press release. The company’s common shares are traded on the Nasdaq Capital Market under the ticker symbol “EYEN.”

Eyenovia is “a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver micro-therapeutics topically to the eye,” according to the release.

Eyenovia’s pipeline is focused on micro-therapeutics for glaucoma and other eye diseases. The company’s website says its technology “will replace outdated dropper technology for improved patient experience and compliance.”

Advertisement

Advertisement

SPONSORED VIDEO

SPONSORED BY SHAMIR

Shamir Glacier PLUS™UV

Utilizing the most advanced technologies, Shamir Glacier PLUS™ UV ensures you receive the most enhanced performance from your lenses.

Promoted Headlines

Advertisement

Advertisement

Subscribe


BULLETINS

Get the most important news and business ideas for eyecare professionals every weekday from INVISION.

Advertisement

Most Popular